Share Name Share Symbol Market Type Share ISIN Share Description
Allergy Therapeutics LSE:AGY London Ordinary Share GB00B02LCQ05 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.875p -4.76% 17.50p 17.25p 17.75p 17.75p 17.375p 17.75p 1,708,500 11:36:10
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 43.2 0.7 0.0 875.0 103.10

Allergy Therapeutics (AGY) Latest News (9)

More Allergy Therapeutics News
Allergy Therapeutics Takeover Rumours

Allergy Therapeutics (AGY) Share Charts

1 Year Allergy Therapeutics Chart

1 Year Allergy Therapeutics Chart

1 Month Allergy Therapeutics Chart

1 Month Allergy Therapeutics Chart

Intraday Allergy Therapeutics Chart

Intraday Allergy Therapeutics Chart

Allergy Therapeutics (AGY) Discussions and Chat

Allergy Therapeutics Forums and Chat

Date Time Title Posts
26/9/201617:30Allergy Therapeutics - AGY -3,148
14/7/201621:04Mike Mitchell Panmure Gordon who covers Allergy Therapeutics PLC (LON:AGY)1
16/12/201510:24Allergy Therapeutics-Transforming Allergy Treatment26
03/2/201213:58Ready to ROCKET?-
04/12/200512:00AGY - Allergy Therapeutics79

Add a New Thread

Allergy Therapeutics (AGY) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
26/09/2016 16:26:1617.385,8001,008.04O
26/09/2016 16:20:5317.2850086.38O
26/09/2016 16:10:4917.384,250738.65O
26/09/2016 16:05:0617.381,542268.00O
26/09/2016 16:04:1017.3814,3842,499.94O
View all Allergy Therapeutics trades in real-time

Allergy Therapeutics (AGY) Top Chat Posts

DateSubject
26/9/2016
09:20
Allergy Therapeutics Daily Update: Allergy Therapeutics is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker AGY. The last closing price for Allergy Therapeutics was 18.38p.
Allergy Therapeutics has a 4 week average price of 18.48p and a 12 week average price of 18.93p.
The 1 year high share price is 33.75p while the 1 year low share price is currently 17.38p.
There are currently 589,158,508 shares in issue and the average daily traded volume is 760,368 shares. The market capitalisation of Allergy Therapeutics is £103,102,738.90.
12/7/2016
11:16
jambo192: "Allergy Therapeutics has been on our Conviction Buy list for 12 months but, following a strong share price performance in 2H15, the stock has been weaker in 1H16. The end-June announcement on US GrassMATAMPL further set the tone on the share price and additional dose-ranging work looks set to add circa 12 months to that development programme vs management expectations, while bringing the timeframe into line with ours. In the meantime, however, +19% YTD constant currency revenue growth sends the message of continued strong commercial traction. With our investment thesis fundamentally unchanged despite the speedbump of the US dose-ranging study, we view the share price reaction offers investors an excellent opportunity." From Panmure's Conviction List Q3 Update: Https://www.research-tree.com/Company/GB00B02LCQ05
09/5/2016
16:17
audigger: Thanks for posting. I guess at some point the company themselves need to engage with a strategy to push their prospects with investors and to energise the share price to catch-with its peers. Right now though they are quite rightly focuses on the clinical trials.
21/4/2016
17:06
thomasthetank1: Read Panmure Gordon & Co's note on ALLERGY THERAPEUTICS, out this morning, by visiting hxxps://www.research-tree.com/company/GB00B02LCQ05 "We added Allergy Therapeutics to the Conviction List in Q315 and the strength of the share price performance during 2H15 saw the stock as one of our top performers. Interim results in March confirmed strong double digit constant currency revenue growth against a flat market backdrop. We expect catalysts in 2016 to include key clinical updates and continued commercial traction underpinning market share gains, so with the share price presently in the mid- 20p range we repeat..."
09/3/2016
08:57
qackers: http://www.directorstalk.com/bullish-gap-up-for-allergy-therapeutics-plc-after-better-fundamentals/ Bullish Gap Up for Allergy Therapeutics plc After Better FundamentalsDavid Hannula | March 9, 2016 The stock of Allergy Therapeutics plc (LON:AGY) gapped up by GBX 0.25 today and has GBX 37.05 target or 34.00% above today’s GBX 27.65 share price. The 6 months technical chart setup indicates low risk for the GBX 162.86 million company. The gap was reported on Mar, 9 by Barchart.com. If the GBX 37.05 price target is reached, the company will be worth GBX 55.37M more. Gaps up are useful for using as a support level and to some extent as a tradeable event. If investors already hold the stock and experience a price gap up, then its usually a good idea to hold the stock for a stronger up move. Back-tests of these patterns indicate that two-thirds of the times the stock performance improves after the gap. The area gaps close 89% of the time, the breakaway gaps, 2%, the continuation gaps 4% and the exhaustion gaps 61%. The stock increased 1.47% or GBX 0.4 on March 8, hitting GBX 27.65. About 26,621 shares traded hands. Allergy Therapeutics plc (LON:AGY) has risen 3.29% since August 6, 2015 and is uptrending. It has outperformed by 8.95% the S&P500. Out of 3 analysts covering Allergy Therapeutics PLC (LON:AGY), 3 rate it “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Allergy Therapeutics PLC was the topic in 13 analyst reports since July 23, 2015 according to StockzIntelligence Inc. Panmure Gordon maintained the stock on March 8 with “Buy” rating. Allergy Therapeutics Plc is a United Kingdom pharmaceutical company. The company has a market cap of 162.86 million GBP. The Firm focuses on the treatment and prevention of allergy with aluminum free products. It has 294.15 P/E ratio. It provides information to healthcare professionals about the prevention, diagnosis and treatment of allergic conditions with focus on allergy vaccination, which is also known as specific immunotherapy or desensitization therapy.
22/2/2016
12:12
jimmyloser: Sir, Am I alone in scratching my head at the share price travails here? Do we have exposure to China? Does the weakened pound impact negatively? Are the various trials all behind schedule? Yours etc
13/10/2015
13:04
qackers: http://www.proactiveinvestors.co.uk/companies/news/116158/allergy-therapeutics-has-major-opportunity-in-us-says-stifel-116158.html Allergy Therapeutics has major opportunity in US, says Stifel 10:19 13 Oct 2015 Just for the grass vaccine allergy alone Stifel is predicting sales of US$400mln by 2023. Allergy Therapeutics has major opportunity in US, says Stifel The company has already invested over US$100mln developing its flagship Pollinex Quattro (PQ) product portfolio for the US market. Allergy Therapeutics (LON:AGY) has a good business in Europe, but it is the US opportunity that can transform the hay fever vaccine group according to broker Stifel. The broker notes the company has already invested over US$100mln developing its flagship Pollinex Quattro (PQ) product portfolio for the US market. After initial delays, a first US product launch is now slated for 2019 and just for the grass vaccine allergy alone Stifel is predicting sales of US$400mln by 2023. With around 1m allergy sufferers in the US receiving allergy immunotherapy (AIT) for their grass allergies each year and an annual treatment cost of around $2,000 per person, the grass AIT market is potentially worth $2bn in the US. Stifel sees Pollinex Quattro Grass achieving a 20% market share. Ragweed and Trees vaccines are expected to follow and from its full Pollinex Quattro portfolio Allergy believes it can generate revenues of between US$800-1,000. Stifel has started its coverage with a target price of 79p, compared to a current share price of 27p, or about 200% upside. Buy is the broker’s investment view. “With multiple catalysts expected over the next 12-24 months, we expect the shares to outperform.” Share Philip Whiterow
21/9/2015
15:22
qackers: http://www.proactiveinvestors.co.uk/companies/news/110974/allergy-therapeutics-chief-expects-company-to-more-active-in-ma-110974.html?utm_source=twitterfeed&;utm_medium=twitter Allergy Therapeutics chief expects company to more active in M&A Share 14:36 21 Sep 2015 “We are now much better placed to be a little bit more active on M&A,” said CEO Manuel Llobet.Allergy Therapeutics (LON:AGY) chief executive Manuel Llobet said he expects to be “more active in M&A” following a sharp rise in the company’s valuation. He told Proactive Investors the advance in the firm’s market capitalisation from £30mln to £145mln would allow it to revisit deals it had been working on. Transactions in this, the growth segment of the drugs industry, are often funded using equity, so having a strong stock price is important. “We are now much better placed to be a little bit more active on M&A,” Llobet said. “Our market cap has gone from £30mln to almost £150mln in a few months and our share price has had a good rally.” Its last purchase, of Spain’s Alerpharma for an initial £2.8mln, is bedding in well, the Allergy CEO said. In fact the integration should be complete by January next year. Llobet updated on progress after the company published results for year to June 30. Revenues from the maker of the Pollinex range of vaccines rose by 11% to £46.6mln in the year to June, giving a £700,000 operating profit. The business generated £2.5mln of cash. A £20mln equity fundraiser in March will bankroll a US clinical study on its Pollinex Quattro Grass product. The shares rose 2.1%, or 0.55p, to 26.55p, after profits beat expectations. Broker Panmure Gordon reckons the stock is worth 47p. “News flow has been strong recently so today’s statement gives investors a chance to reflect, again, on market-outperformance across Europe, the Alerpharma acquisition and the US opportunity for Pollinex Quattro Grass,” said analyst Mike Mitchell.
05/3/2014
07:48
jimmyloser: I have thought of that and have read the prospectus and cannot see why they would at this stage. Having read that prospectus, I really am baffled as to why AGY share price is in pennies NO RAMP INTENDED. There have been encouraging signs that the board are now starting to market the company better. I repeat myself again. THIS MONTH IS HUGE FOR ALL INVOLVED HERE We have results on the 24th and 'hopefully' some solid USA news along with the Circassia floatation. I am shamefaced but will openly admit that when I bought into Allergy in January that I didn't realise that I had a potentially massive tiger by the tail. Really is the best money I have invested.
20/2/2014
13:59
audigger: Looks like the demand for these is still high and the availability limited hence another leg-up. Long may it continue. Clealry there is a linear relationship between the AGY share price and the miles that Cube's dog gets walked........
10/2/2014
18:06
cube boss: Apart from an old piece of news in a glossy magazine, we haven't had any news and we are climbing very nice! I think we are rising at a fast rate because the news that is due, it's going to be company changing! it's going to put us in a different league. Remember the Multi-billion market in the US alone, our vaccine will change the way people live in the US. It's like an oil company who have just spudded and are expecting multi million barrels in a couple of months if all goes well. The only difference is, Allergy Therapeutics "CAN'T" have a duster!! we know this works and will change peoples life's. AGY share price has been suppressed for the last 7 years since the FDA put the clinical hold on, now people are starting to wake up. So for these reasons, I can't help being a BIG Believer..:0)))
Allergy Therapeutics share price data is direct from the London Stock Exchange
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:42 V: D:20160927 01:56:18